Pay in 4 interest-free payments of $6.73 Learn more
Ships within 48 hours Β· Estimated delivery Aug 1 - Aug 6
[DOI] [PubMed] [Google Scholar] 52.Yamada Y., Katagiri H., Hamamoto Y., Deenadayalan S., Navarria A., Nishijima K., Seino Y., PIONEER 9 Investigators Dose-response, efficacy, and safety of oral semaglutide monotherapy in Japanese patients with type 2 diabetes (PIONEER 9): A 52-week, phase 2/3a, randomised, controlled trial
[DOI] [PubMed] [Google Scholar] 37.Singh S, et al
When patients are fully informed about the trade-offs, they are more likely to commit to consistent therapy
- Third-party tested for quality & purity
Frontline Gastroenterol 2023;14(6):5216
The trial found that after 5 years, Wegovy significantly reduced the risk of death from heart disease by 15% and reduced the risk of cardiovascular events including nonfatal heart attacks and strokes by 20%, compared to an inactive placebo
US$ 20.76
US$ 22.05
US$ 25.01
US$ 23.36
US$ 29.89
